Senti Biosciences (SNTI) Accounts Payables (2021 - 2025)

Senti Biosciences has reported Accounts Payables for 5 years, with the latest figure at $5.4 million in Q4 2025.

• For the quarter ending Q4 2025, Accounts Payables rose 268.23% year-over-year to $5.4 million; the trailing twelve-month figure through Dec 2025 stood at $5.4 million (up 268.23% YoY), and the FY2025 full-year result was $5.4 million, up 268.23% from the prior year.
• Accounts Payables for Q4 2025 stood at $5.4 million, up from $5.1 million in the prior quarter.
• The five-year high for Accounts Payables was $12.6 million in Q4 2022, with the low at $28.0 in Q1 2021.
• Average Accounts Payables over 5 years is $4.1 million, with a median of $3.8 million recorded in 2025.
• Year-over-year, Accounts Payables surged 14015194.12% in 2022 and slumped 76.34% in 2024.
• Tracing SNTI's Accounts Payables over 5 years: stood at $5.3 million in 2021, then jumped by 135.9% to $12.6 million in 2022, then slumped by 52.87% to $5.9 million in 2023, then slumped by 75.47% to $1.5 million in 2024, then soared by 268.23% to $5.4 million in 2025.
• The last three Accounts Payables figures came in at $5.4 million (Q4 2025), $5.1 million (Q3 2025), and $3.6 million (Q2 2025), per Business Quant data.

Peer Comparison